Delivering on the Promise of
State-of-the-art Bispecific Antibody Development
Delivering on the Promise of Bispecifics: State-of-the-Art Bispecific Antibody Development
That's the power you have with KBI and Selexis.
That's the power of together.
DOWNLOAD THE PDF TODAY
An off-the-shelf therapy that can be used immediately, rather than one that must be manufactured individually for each patient (such as chimeric antigen receptor T-cell therapies, or CAR-Ts), can be a lifesaving treatment for patients who encounter difficult-to-treat or rapidly progressing diseases, including many cancers.
The promise of bispecific antibodies (bsAbs) stems from their off-the-shelf nature and ability to bind to two or more epitopes, thereby performing multiple functions.
Given the complexity of bsAbs, a cell-line development platform for these proteins must contain three key features to be sufficiently robust for generating bsAbs:
- Stable and high expression of bsAbs
- Straightforward early screening
- A robust cell line that can handle stressors
Furthermore, advancing bsAbs from the bench into the clinic requires process development, analytical methods, and scale-up for cGMP manufacturing.
The Selexis/KBI partnership combines best-in-class cell line development with science-driven, experienced contract development and manufacturing in a leverageable, integrated workflow that generates high-quality clinical bulk drug substances under accelerated timelines.